Skip to main content
Equibles

ACADIAN ASSET MANAGEMENT LLC

Position in NXTC — NextCure, Inc.

CIK 916542 Boston, MA
Back to NXTC Full portfolio

Position in NXTC

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$30,371
-$172,356 QoQ
Shares Held
18,982
0.0% QoQ
Ownership
0.415%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#17
of 30 holders
Holding Since
Mar 2021
22 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NXTC Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ACADIAN ASSET MANAGEMENT LLC holds $732,389,014 across 168 Biotechnology names. NXTC ranks #159 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INCY
Incyte Corp
 1,664,999 $188,744,286
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,440 $98,170,137
3 IMCR
Immunocore Holdings plc
 1,209,894 $38,414,134
4 RIGL
Rigel Pharmaceuticals Inc
 591,686 $23,146,756
5 EXEL
Exelixis, Inc.
 421,444 $22,930,768
6 VRTX
Vertex Pharmaceuticals Inc / Ma
 42,122 $20,923,261
7 TBPH
Theravance Biopharma, Inc.
 1,174,910 $19,973,470
8 PRTA
Prothena Corp Public Ltd Co
 2,010,645 $19,684,214

All Filings in NXTC

Export CSV
22 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $30,371 18,982
2026-03-31 $202,727 18,982
2025-12-31 $379,795 26,765
2025-09-30 $214,915 36,675
2025-06-30 $224,682 488,440
2025-03-31 $234,451 488,440
2024-12-31 $376,587 488,440
2024-09-30 $669,162 488,440
2024-06-30 $776,619 488,440
2024-03-31 $1,089,221 488,440
2023-12-31 $556,821 488,440
2023-09-30 $630,087 488,440
2023-06-30 $879,191 488,440
2023-03-31 $722,891 488,440
2022-12-31 $606,950 430,461
2022-09-30 $826,754 300,638
2022-06-30 $1,440,159 306,417
2022-03-31 $1,625,106 334,384
2021-12-31 $1,916,243 319,374
2021-09-30 $690,351 102,426
2021-06-30 $809,777 100,844
2021-03-31 $353,132 35,278